Cite
HARVARD Citation
Takeda, M. et al. (2016). Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open‐label, randomized, phase 2 trial. Cancer. 122 (7), pp. 1050-1059. [Online].